procarbazine
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | MATULANE | — | 1969-07-22 | fda.gov ↗ |
Trials 64 · started per year
Also used as a comparator or background therapy in 20 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06541665 Background | May 2024 → Apr 2028 expected | primary central nervous system lymphoma | Ono Pharmaceutical Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT03576378 Background | Aug 2018 → Oct 2023 | Hodgkins lymphoma | Spanish Lymphoma Cooperative Group | Unknown | No outcome recorded |
| Phase 1/2 | NCT02315326 Background | Dec 2014 → Jan 2026 | central nervous system non-hodgkin lymphoma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 27 trials | ||||||
| Phase 2 | NCT07015242 Background | Nov 2025 → Jan 2028 expected | lymphoma | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | Recruiting | No outcome recorded |
| Phase 2 | NCT02298283 Background | Apr 2015 → Jul 2020 | Hodgkins lymphoma | The Lymphoma Academic Research Organisation | Completed | No outcome recorded |
| Phase 2 | NCT01569204 Comparator | Oct 2012 → Mar 2014 | Hodgkins lymphoma | University of Cologne | Completed | No outcome recorded |
| Phase 2 | NCT01399372 Background | Sep 2011 → Mar 2020 | chemotherapy-induced toxicity, cognitive disorder, lymphoma, radiation-induced disorder | Radiation Therapy Oncology Group | Completed | No outcome recorded |
| Phase 2 | NCT00503594 Comparator | Jul 2007 → Jul 2010 | lymphoma | Assistance Publique - Hôpitaux de Paris | Unknown | No outcome recorded |
| Phase 2 | NCT00079105 Comparator | Jan 2004 → Dec 2010 | lymphoma | Newcastle-upon-Tyne Hospitals NHS Trust | Completed | No outcome recorded |
| Phase 2 | NCT00431561 Comparator | Apr 2003 → Mar 2009 | anaplastic astrocytoma, glioblastoma | Isarna Therapeutics GmbH | Completed | No outcome recorded |
| Phase 310 trials | ||||||
| Phase 3 | NCT06830421 Comparator | Aug 2023 → Aug 2029 expected | primary central nervous system lymphoma | University Hospital Freiburg | Recruiting | No outcome recorded |
| Phase 3 | NCT04702581 Background | Dec 2021 → Dec 2030 expected | oligodendroglioma | Hospices Civils de Lyon | Recruiting | No outcome recorded |
| Phase 3 | NCT05331521 Comparator | Apr 2021 → Mar 2033 expected | oligodendroglioma | University Hospital Heidelberg | Recruiting | No outcome recorded |
| Phase 3 | NCT02661503 Comparator | Jul 2016 → Dec 2022 | classic Hodgkin lymphoma | University of Cologne | Unknown | No outcome recorded |
| Phase 3 | NCT02444000 Background | Sep 2015 → Oct 2022 | malignant glioma | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Phase 3 | NCT01356680 Background | Jan 2012 → Mar 2020 | Hodgkins lymphoma | University of Cologne | Completed | No outcome recorded |
| Phase 3 | NCT01358747 Comparator | May 2011 → ? | Hodgkins lymphoma | Centre Hospitalier Universitaire Dijon | Completed | No outcome recorded |
| Phase 3 | NCT00433459 Comparator | Jan 2007 → Jan 2013 | lymphoma | Christine Mauz-Körholz | Completed | No outcome recorded |
| Phase 3 | NCT00003788 Background | Apr 1998 → ? | central nervous system cancer | Colorado Health Foundation | Unknown | No outcome recorded |
| Phase 3 | NCT00577993 Comparator | Mar 1998 → Aug 2017 | lymphoma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
Evidence & citations 19 cited values
Every value below carries the sentence it was read from. 85 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | procarbazine | “Control chemotherapy treatment will be chosen from any of the following standard-of-care chemotherapy drugs or combinations:
* Carboplatin;
* Irinotecan;
* Etoposide;
*...” NCT03632135 ↗75“bleomycin 10 units/m\^2 IV on Day 8 etoposide 200 mg/m\^2 IV on Days 1, 2 and 3 doxorubicin 35 mg/m\^2 IV on Day 1 cyclophosphamide 1250 mg/m\^2 IV on Day 1 vincristine 1.4...” NCT01118026 ↗ “BACOPP-D regimen which includes cyclophosphamide, adriamycin, dacarbazine, procarbazine, prednisolone, bleomycin and vincristine” NCT00188149 ↗ “temozolomide: capsules, up to 200 mg/sqm/day, 5 days per cycle; PCV (procarbazine, CCNU, vincristine): standard regimen” NCT00431561 ↗ “bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPPesc)” NCT01652261 ↗ “Procarbazine100 mg/m2/b.m./die 1°- 7° Prednison40 mg/m2/b.m./die 1°-14°” NCT00795613 ↗ “cyclophosphamide, procarbazine, etoposide and prednisone (BEACOPP)” PMID 28601705 ↗ Jun 2017 “Days 8-21: Procarbazine 60 mg/m2 orally (capped at 100 mg).” NCT05331521 ↗ “plus Procarbazine 100mg/m2 by mouth (OR) on Day1 through 5” NCT03576378 ↗ “Prednisone, Cyclophosphamide, Etoposide, Procarbazine” NCT00151281 ↗ “Cap Procarbazine 100mg/m2 Day 1 to Day 7 PO” NCT01304849 ↗ “Days 8 to 21: procarbazine 60 mg/m2 orally” NCT02444000 ↗ “Days 8 to 21: Procarbazine 60 mg/m2 orally” NCT04702581 ↗ “Procarbazine 100 mg/m2 orally day 1 to 7” NCT00433433 ↗ “100 mg/m2 oral procarbazine on days 1-7” PMID 30658935 ↗ Jan 2019 “daily procarbazine (PCB, 50 mg p.o.” NCT01124240 ↗ “Procarbazine” NCT00592111 ↗ |
| Known as | Ibenzmethyzine hydrochloride | ChEMBL registry synonym — accepted as the source's own label CHEMBL1321 ↗ |
| Known as | Matulane | ChEMBL registry synonym — accepted as the source's own label CHEMBL1321 ↗ |
| Known as | Natulan | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02800447 ↗ |
| Known as | NCI-C 01810 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1321 ↗ |
| Known as | NSC-77213 | “Procarbazine, PCB, NSC-77213” NCT00002462 ↗ |
| Known as | PCB | “Procarbazine, PCB, NSC-77213” NCT00002462 ↗ |
| Known as | Procarbacine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00284271 ↗ |
| Known as | Procarbazina | ChEMBL registry synonym — accepted as the source's own label CHEMBL1321 ↗ |
| Known as | Procarbazine hcl | ChEMBL registry synonym — accepted as the source's own label CHEMBL1321 ↗ |
| Known as | procarbazine hydrochloride | “Drug: procarbazine hydrochloride” NCT00002569 ↗13“Drug: procarbazine hydrochloride” NCT00079105 ↗ “Drug: Procarbazine Hydrochloride” NCT00002463 ↗ “Drug: procarbazine hydrochloride” NCT00003375 ↗ “Drug: procarbazine hydrochloride” NCT00049595 ↗ “Drug: procarbazine hydrochloride” NCT00678327 ↗ “Drug: procarbazine hydrochloride” NCT00666484 ↗ “procarbazine hydrochloride” NCT00002840 ↗ |
| Known as | Procarbazini hydrochloridum | ChEMBL registry synonym — accepted as the source's own label CHEMBL1321 ↗ |
| Known as | RO 4 6467/1 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1321 ↗ |
| Known as | RO 4-646711 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1321 ↗ |
| Known as | RO-4-6467 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1321 ↗ |
| Known as | RO-4-6467 FREE BASE | ChEMBL registry synonym — accepted as the source's own label CHEMBL1321 ↗ |
| Known as | RO-4-6467 HYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL1321 ↗ |
| Modality | Small molecule | — CHEMBL1321 ↗ |
| Route | Oral | “oral procarbazine and oral prednisone on days 1-10” NCT00002463 ↗ |